- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Geron Corp.
Headquarters: Menlo Park, CA, United States of America
Website: https://www.geron.com/
Year Founded: 1990
Status: Public
Industry Sector: HealthTechnology
CEO: Dawn Carter Bir
Number Of Employees: 229
Enterprise Value: $2,125,040,694
PE Ratio: -5.2
Exchange/Ticker 1: NASDAQ:GERN
Exchange/Ticker 2: N/A
Latest Market Cap: $904,416,512
BioCentury | Mar 13, 2025
Management Tracks
Scarlett steps down as CEO of Geron
Plus: Purespring names Haseeb Ahmad CEO, and updates from Cellevate and Moffitt Cancer Center
BioCentury | Dec 14, 2024
Data Byte
BridgeBio, Geron follow U.S. approvals with nods from EMA’s CHMP
November meeting highlights also include a pair of firsts for rare genetic diseases, and label expansions for eight approved drugs
BioCentury | Sep 10, 2024
Management Tracks
Vir names Jason O’Byrne CFO
Plus: Maslowski to become CEO of Forge as Miller steps down, and updates from Sofinnova Partners, Abingworth, PATH and more
BioCentury | Jul 23, 2024
Management Tracks
Armstrong takes new role at Dana-Farber
Plus: The Carlyle Group’s Rubenstein to join Moderna’s board and updates from Geron, Vedanta, Vericel, Metrion and PharmaEssentia
BioCentury | Jul 17, 2024
Data Byte
FDA’s five NME approvals in June bring 1H24 total to 21
Ipsen’s Iqirvo, Geron’s Rytelo among June highlights
BioCentury | Jun 7, 2024
Regulation
At long last, Geron wins FDA approval of first drug
The 34-year-old company will bring to market Rytelo imetelstat for some patients with myelodysplastic syndromes
BioCentury | Jun 5, 2024
Data Byte
15 PDUFA dates on FDA’s roster in June
Upcoming decisions include HER3 ADC from Daiichi-Merck and full approval for Sarepta’s DMD gene therapy
BioCentury | Sep 13, 2023
Management Tracks
CEO Nick Leschly shifting to chair as 2seventy bio restructures
Plus: CFO Galá promoted at Jazz, and updates from Geron, Mirum, ReNAgade,
BioCentury | Aug 22, 2023
Finance
Aug. 22 Quick Takes: Forty51-backed Mysthera launches to development autoimmune therapies
Plus: FDA lifts hold on Fulcrum’s trial and more, panel to discuss Geron’s imetelstat
BioCentury | Jan 7, 2023
Finance
Follow-ons end year on high note
17 biopharmas raised $2B in December; Geron deal helps kick off New Year
Items per page:
1 - 10 of 439